Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT00193895Phase 3Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Apr 2005
- Primary completion
- Mar 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of carboplatin in cutaneous squamous cell carcinoma (cSCC), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Loco-regional Control at 2 years. Started Apr 2005; status: completed.
02
Drugs
carboplatin
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT00193895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193895.